The global 3D bioprinting market is estimated to expand at a considerable CAGR during the forecast period, 2021 – 2028. 3D bioprinting is an extended branch of 3D printing. 3D bioprinting constructs living blood vessels, bone, tissue with a potential to produce organs for use in medical training and testing. 3D bioprinting uses additive manufacturing as its foundation, unlike 3D printing, which uses a layering process to produce solid objects.
The global 3D Bioprinting market is expected to develop slowly as compared to conventional 3D printing, due to the cellular intricacy of the human body. 3D bioprinting may produce patient-specific tissue, delivering precise, focused, and personalized treatments.
However, it has a long road to cover before reaching a point of fully functioning organs which can be used for transplantation. 3D bioprinting can be the answer to global organ shortage and rising disinclination to test new pharmaceutical, chemical, and cosmetic products on animals.
Market Trends, Drivers, Restraints, and Opportunities
- The market growth can be attributed to an inadequate number of organ donors and rising geriatric population with respiratory diseases.
- Technological innovations, increasing R&D investments, and rising occurrence of chronic diseases are anticipated to boost the market growth during the forecast period.
- Due to rising COVID-19 cases, there is an increase in demand for 3D bioprinting, thereby propelling the market growth.
- The demand for skilled professionals, who can efficiently manage complex functioning of 3D bioprinting systems is rising, but availability of such professionals is limited which restrains the growth of the market.
- 3D bioprinting uses living cells for products to be used in medical applications. The use of bioprinted products has raised biosafety concerns. Moreover, concerns over biomaterials used and the techniques of waste elimination are major factors that hamper the implementation of 3D bioprinting.
Scope of 3D Bioprinting Market Report
The report on the global 3D bioprinting market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
3D Bioprinting Market Segment Insights
Pneumatic extrusion segment to account for a considerable market share
On the basis of technology, the global 3D bioprinting market can be segmented into syringe, pneumatic extrusion, inkjet, laser, and others. The pneumatic extrusion segment is anticipated to hold a sizeable market share during the forecast period, owing to the constant technological developments in the pneumatic extrusion tools.
Drug testing and development segment to grow at a rapid pace
In terms of applications, the global 3D bioprinting market can be fragmented into drug testing and development, regenerative medicine, food testing, research, and others. The drug testing and development segment is expected to grow at a substantial CAGR, as 3D bioprinting can severely decrease the need for animal trials, which is ethically beneficial as well as cost-effective.
Asia Pacific holds a key share of the global market
Based on regions, the global 3D bioprinting market can be classified as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The market in Asia Pacific region is projected to grow at a significant CAGR during the forecast period, which is driven by rising research initiatives, increasing demand for organ transplants, and increasing presence of key industry players in the Asia Pacific region. The markets in India and China are anticipated to grow at a considerable CAGR, due to the increasing support from government and rising demand for surgeries.
The global 3D bioprinting market has been segmented on the basis of
- Pneumatic Extrusion
- Extracellular Matrices
- Drug Testing and Development
- Regenerative Medicine
- Food Testing
- North America
- Latin America
- Asia Pacific
- Middle East & Africa
- Major players in the global 3D bioprinting market includes 3D Bioprinting Solutions, Allevi, Inc, Cellink Global, Cyfuse Biomedical K.K., Envisiontec, Inc., Inventia Life Science Pty Ltd., Organovo Holdings, Inc., Poietis, Regemat 3D S.L., and Vivax Bio, LLC. The 3D bioprinting market is competitive and involves several players. The key players have a major share in the market and are focused on expansion in various regions. Companies adopt strategies such as investments in R&D, joint ventures, acquisitions, and product launches to increase their market share and market presence.
- In 2020, 3D Systems and CollPlant Biotechnologies joined hands to a collaborative development agreement, which can facilitate ingenious innovations in the biomedical industry. The alliance is anticipated to develop regenerative medicines with the assistance of 3D bioprinting.
- CELLINK recently launched BIO X6, a 6-printhead bioprinting technology that permits the usage of diverse tools, cells, and materials. The system provides a smart exchangeable printhead technology supported by patented Clean Chamber Technology of CELLINK.
- EnvisionTEC currently supports PrintParts to tackle the supplies required for COVID testing in New York. The company plans to increase the volume and quality of its 3D bioprinting applications.
- In 2020, REGEMAT 3D in its efforts to expand and fulfill its research needs, raised a sum of €700,000 from the Centre for the Development of Industrial Technology (CDTI), the Horizon 2020 European Union (EU) funding program, and Initial Coin Offering (ICO). REGEMAT 3D unveiled a novel service that helps in producing bioreactors for maturing tissues.
- Inventia Life Science Pty Ltd declared in April 2020, that its 3D bioprinting platform Rastrum can act as a powerful instrument for producing 3D lung microtissues, which can be used in COVID-19 therapies.